Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

397.36 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7
Open 397.36
Bid (Size) 367.00 (1)
Ask (Size) 408.74 (1)
Prev. Close 397.36
Today's Range 397.36 - 397.36
52wk Range 316.43 - 448.40
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock
Vertex just laid claim to an asset that might be very valuable. 
Via The Motley Fool
Could This Stock Be the Next Biotech Buyout?
Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease. 
Via The Motley Fool

Performance

YTD
-3.30%
-3.30%
1 Month
-3.41%
-3.41%
3 Month
-9.17%
-9.17%
6 Month
+6.25%
+6.25%
1 Year
+21.24%
+21.24%

More News

Read More
The Analyst Landscape: 16 Takes On Vertex Pharmaceuticals
Via Benzinga
Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
Via Benzinga
Vertex Pharmaceuticals: Buy, Sell, or Hold?
Via The Motley Fool
Stocks Bounce Back With Tech, Gold Gaining After Modest Producer Inflation Data: What's Driving Markets Thursday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024
Via InvestorPlace
Raymond James Just Raised Its Price Target on Nvidia (NVDA) Stock
Via InvestorPlace
Apple Spyware Warning: What to Know About ‘Mercenary Spyware Attack’ Alerts
Via InvestorPlace
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Via InvestorPlace
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Via Investor's Business Daily
Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune
Via Benzinga
Wall Street Braces For Another Red Day Ahead Of More Inflation Data While Bitcoin Holds Above $70K: Analyst Sees Any Pullback As 'Phenomenal Buying Opportunity'
Via Benzinga
Topics Economy
Exposures Interest Rates
Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal
Via Investor's Business Daily
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
From Alpine Immune Sciences, Inc.
Via Business Wire
Vertex to Announce First Quarter 2024 Financial Results on May 6
From Vertex Pharmaceuticals Incorporated
Via Business Wire
This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?
Via The Motley Fool
Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse'
Via Benzinga
3 High-Growth Biotech Stocks Investors Shouldn’t Sleep On in April
Via InvestorPlace
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Via The Motley Fool
Got $1,000? 2 Bulletproof Stocks to Buy in 2024 and Hold for the Long Haul
Via The Motley Fool
Biotech Sector Nears Breakout: Will it Outperform in Q2?
Via MarketBeat
Topics ETFs
Missed the "Magnificent Seven"? Try Buying These 3 Forever Stocks Instead
Via The Motley Fool
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.